Medtech start-ups like Fractyl Laboratories can inspire with promising technologies that may someday cut down diabetes.
But those stories run on capital, not optimism.
Last month, Fractyl filled its cash tank with a $44 million Series D round coming from new investors including GV, True Ventures, and IDO Investments as well as an undisclosed investor.
In this interview, co-founder and CEO Harith Rajagopalan, MD, PhD, discusses how much time he commits to raising new rounds of capital. As CEO, “you and you alone have to make sure you have enough cash in the bank to achieve your objective,” he says.
Dr. Rajagopalan also:
- Offers advice to Medtech CEOs pitching their own fund-raising story.
- Discusses the importance of building the right board of directors. In November, Fractyl announced the addition of Sen. William W. Bradley and Dr. John Amatruda to the company’s board of directors. How does a high-profile board support a Medtech CEO?
- Updates us on Fractyl’s clinical progress.
- Explains the company’s connection to the influential diabetes patient community.